Trecora Resources (NYSE:TREC) shares increased 6.69% in last trading session and ended the day at $10.52. TREC Gross Margin is 23.40% and its has a return on assets of 8.30%. Trecora Resources (NYSE:TREC) quarterly performance is -27.85%.
Trecora Resources (NYSE:TREC) said that, Anellotech has begun construction of its development and testing facility (TCat-8) in Silsbee, Texas, US, for cost-competitive renewable chemicals from non-food biomass.
Brunswick Corporation (NYSE:BC) ended the last trading day at $39.85. Company weekly volatility is calculated as 5.94% and price to cash ratio as 5.54. Brunswick Corporation (NYSE:BC) showed a weekly performance of -5.64%.
Brunswick Corporation (NYSE:BC) announced that it has acquired Cybex International Inc., a leading maker of commercial fitness equipment, for $195 million, subject to a working capital adjustment. Cybex will join Brunswick’s Life Fitness Division’s portfolio of leading brands.
On 29 January, Kate Spade & Company (NYSE:KATE) shares increased 4.21% and was closed at $17.81. KATE EPS growth in last 5 year was 19.70%. Kate Spade & Company (NYSE:KATE) year to date (YTD) performance is 0.23%.
Kate Spade & Company (NASDAQ:KATE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, Market Beat reports. The firm currently has a $20.00 price target on the stock. Zacks Investment Research‘s price target points to a potential upside of 12.30% from the company’s current price.
Radius Health, Inc. (NASDAQ:RDUS) shares fell -2.53% in last trading session and ended the day at $32.03. RDUS has a return on assets of -31.70%. Radius Health, Inc. (NASDAQ:RDUS) quarterly performance is -52.51%.
On 27 January, Radius Health, Inc. (NASDAQ:RDUS) announced that it has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals (NYSE:NVS) to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib)*, a cyclin-dependent kinase (CDK) 4/6 inhibitor. Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with targeted agents such as CDK 4/6 inhibitors in pre-clinical models.
Dover Motorsports Inc. (NYSE:DVD) caters to the Services space. It has a net profit margin of -12.80% and weekly performance is 4.95%. On the last day of trading company shares ended up at $2.22. Dover Motorsports Inc. (NYSE:DVD) distance from 50-day simple moving average (SMA50) is -0.63%.
On 28 January, Dover Motorsports Inc. (NYSE:DVD) reported its results for the fourth quarter and year ended December 31, 2015. Revenues for the fourth quarter of 2015 were $21,016,000 compared with $157,000 in the fourth quarter of 2014. Operating and marketing expenses were $11,940,000 in the fourth quarter of 2015 compared to $990,000 in the fourth quarter of 2014. Both increases are due to the timing of our 2015 fall NASCAR race weekend.
Leave a Reply